Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2022-01-06 Director's Dealing
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-06 English
SABBY 13G-A TTNP 1.03.22
Major Shareholding Notification
2022-01-03 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated December 30, 2021. The key content is the submission of matters to a vote of security holders at the company's annual meeting, including election of directors, ratification of auditors, and advisory votes on executive compensation. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is about the official results from shareholder votes at the Annual Meeting, not the meeting materials or the full annual report. The length is about 4700 characters, consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA.
2021-12-31 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amendment to the company's bylaws regarding the quorum requirement for stockholder meetings. There is no financial data or detailed financial performance information, nor is it a transcript, presentation, or voting results announcement. The document is not an annual or quarterly report, nor is it a proxy solicitation or remuneration report. It is a regulatory filing announcing a corporate governance change. Given the nature of the Form 8-K and the content, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters, but it contains substantive information about a governance change rather than just announcing a report publication, so it is not RPA. Confidence is high due to clear identification of the document type and content.
2021-12-29 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.